CureVac will withdraw its first-generation Covid-19 vaccine candidate and focus on collaborating with GlaxoSmithKline to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company has said.
CureVac said it would abandon its application for regulatory approval from the European Medicines Agency for its first-generation vaccine candidate CVnCoV after late-stage trials delivered disappointing results in June with 47 per cent efficacy.
There would be a potential overlap with approval timelines for a second-generation candidate.
Read more from Reuters here.
